Vollständiger Abstract
Worum geht es in dieser Arbeit?
Abstract Background The endpoint Time to Subsequent Therapy (TTST) is an intermediate endpoint used in research and regulatory assessments. TTST denotes initiation of subsequent therapy and is a clearly definable, clinically relevant event for healthcare professionals. However, it has not been systematically established to which extent TTST is subjectively meaningful to patients. The objective of this study was to define TTST as a patient-relevant intermediate endpoint. Methods The study examined five oncological indications (breast cancer, prostate cancer, melanoma, multiple myeloma, and non-small cell lung cancer) using a systematic literature review, analysis of case report forms used in international randomized controlled trials, review of German Federal Joint Committee (G-BA) documents, semi-structured interviews and a two-stage Delphi survey with healthcare professionals, patients, and relatives. Results A total of 35 individuals participated in qualitative interviews. Most of them rated TTST as particularly significant. The Delphi Survey included 264 interviewees in round one, and 117 in round two. Patient-relevance of TTST was confirmed by 81% of respondents (95% confidence interval 76%, 85%). Nine treatment scenarios that justify TTST were identified. To capture patient-relevance, prospective collection of reasons for and consequences of therapy change are required. A checklist with standardized response formats plus free-text fields was developed: a comprehensive master checklist for flexible, complete documentation and a short version focused on therapy change-specific items. Conclusions TTST is an intermediate endpoint whose systematic documentation of characteristics demonstrating patient-relevance can be standardized in research and clinical practice using the developed checklists.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Bianca Biedenweg, Thorsten Ruppert, Thomas Kohlmann, Martin Danner, Anja Mehnert-Theuerkauf, Diana Lüftner, Ulrike Filippig, Janine Ziemann, Ulrike Osowski, Peter Kaskel
- Quelle
- Journal of Cancer Research and Clinical Oncology
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 1432-1335
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Bianca Biedenweg, Thorsten Ruppert, Thomas Kohlmann, Martin Danner, Anja Mehnert-Theuerkauf, Diana Lüftner, Ulrike Filippig, Janine Ziemann, Ulrike Osowski, Peter Kaskel (2026). Time to subsequent therapy (TTST) as an endpoint in clinical studies: development of standardized documentation of subsequent therapy through systematic literature review, expert interviews, and Delphi survey. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06583-w
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1